WHAT IS CLAIMED IS:

5

10

15

20

25

30

35

- 1. A composition, comprising an anti-TNF chimeric immunoglobulin chain, comprised of at least part of a human immunoglobulin constant region and at least part of a non-human immunoglobulin variable region, said chain capable of binding an epitope specific for human $TNF\alpha$.
- 2. A composition according to claim 1, wherein said chain is a heavy chain or a light chain.
- 3. A composition according to claim 1, wherein said constant region is of human origin.
- 4. A composition according to claim 1, wherein said biological activity binding of said chain to $TNF\alpha$ has a neutralizing effect on a pathologic activity of $TNF\alpha$.
- 5. A composition according to claim 1, wherein said chain has an antigen binding region which binds residues 87-108, or both 9-80 and 87-108, of hTNF α of SEQ ID NO:1.
- 6. A composition according to claim 1, wherein said chain, fragment or region does not bind to an epitope selected from the group consisting of amino acids 11-13, 37-42, 49-57 or 155-157 of hTNF α of SEQ ID NO:1.
- 7. A demposition according to claim 1, wherein said chimeric immunoglobulin chain comprises two light chains and two heavy chains, each of said chains comprising at least part of a constant region and at least part of a variable region, said variable region capable of binding an epitope specific for human $TNF\alpha$.
- 8. A composition according to claim $\frac{4}{1}$, wherein said epitope is a neutralizing epitope of human TNF α , under physiological conditions.
- 9. A composition according to claim 1, wherein said chain does not bind to $TNF\beta$.
- 10. A composition according to claim 4, wherein said variable region is of murine origin.
- 11. A composition according to claim 1, wherein said variable region is derived from a high affinity murine monoclonal immunoglobulin chain which binds to a neutralizing epitope of human $TNF\alpha$.

I:\gkt\app\newapp le1v3d.app

158

February 4, 1994

- 12. A composition according to claim 11, wherein said neutralizing epitope is at least 5 amino acids selected from the group consisting of residues 87-108 and both 59-80 and 87-108 of SEQ ID NO:1.
- 13 A composition according to claim 12, wherein said epitope is selected from residues 87-108 of SEQ ID NO:1.
- 14. A composition according to claim 12, wherein said epitope is selected for both 59-80 and 87-108 of SEQ ID NO:1.
- 15. A composition according to claim 11, wherein said murine monoclonal chain competitively inhibits the binding of monoclonal immnuoglobulin chain A2 or cA2 to TNFα.
- 16. A composition according to claim 12, wherein said murine monoclonal chain is A2.
- 17. A composition according to claim 12, wherein said murine monoclonal chain is cA2.
- 18. A composition according to claim 1, wherein said binding of said chain to human αTNF has an affinity, measured as an association constant (Ka), of at least 1 x 10⁸ liter/mole.
- 19. A composition according to claim 18, wherein said affinity is at least 1 x 10° liter/mole.
- 20. A composition according to claim 4, wherein said chain neutralizes human TNF α with an ID50 of at least about 1 μ g/ml.
- 21. A composition according to claim 20, wherein said chain neutralizes human TNF α with an ID50 of at least about 100 ng/ml.
- 22. A composition according to claim 21, wherein said chain neutralizes human TNF α with an ID50 of at least about 15 ng/ml.
- 23. A composition according to claim 1, wherein said chain is in detectably labeled form.
- 24. A composition according to claim 1, wherein said chain is produced by a hybridoma or recombinantly.
 - 25. A composition, comprising an anti-human TNF α

I:\gkt\app\newapp le1v3d.app

5

10

15

20

25

30

- chain, or a fragment or region thereof, having an anti-TNF binding region, or fragment thereof, corresponding to a
 - (a) murine monoclonal chain of monoclonal chain A2;(b) chimeric mouse-human monoclonal chain, fragment
- or region of monoclonal chain cA2.

or

5

10

15

20

25

30

35


- 26. A composition, comprising a human TNF α peptide comprising at least 5 amino acids selected from the group consisting of amino acids residues 87-108 and both residues 59-80 and 87-108 of hTNF α of SEQ ID NO:1, wherein said peptide comprises an epitope of an anti-TNF immunoglobulin chain according to claim 1, or a fragment or region thereof, having anti-TNF neutralizing activity by binding to a TNF sequence other than a receptor binding locus, such that anti-TNF chain binding to a TNF receptor is substantially inhibited.
- 27. A composition, comprising a TNF peptide according to claim 23, consisting essentially of 3 to 22 amino acid poly-peptides having at least one sequence selected from the group consisting of:

Tyr-Ser-Gln-Ver-Leu-Phe-Lys-Gly-Gln-Gly-Cys-Pro-Ser-Thr-His-Val-Leu-Leu-Thr-His-Thr-Ile, as amino acids 59-80 of SEQ ID NO:1; and

Tyr-Gln-Thr-Lys-Val-Asn-Leu-Leu-Ser-Ala-Ile-Lys-Ser-Pro-Cys-Gln-Arg-Glu-Thr-Pro-Glu-Gly as amino acids 87-108 of SEQ ID NO:1.

- 28. A pharmaceutical composition, comprising a chimeric chain according to claim 1, or a fragment, region thereof, or a pharmaceutically acceptable ester, ether, sulfate, carbonate, glucuronide or salt thereof, and a pharmaceutically acceptable carrier.
- 29. A method of use of a composition of claim 1, comprising administering to an animal a TNF inhibiting amount of a pharmaceutical composition according to claim 24.
- 30. A method according to claim 25, wherein said composition is administered in an amount of 0.1 to 50 mg/kg.
- 31. A method of use of a composition according to claim 1, for removing from a sample a $TNF\alpha$, a fragment

I:\gkt\app\newapp le1v3d.app



- (a) contacting said sample to a device containing a composition according to claim 1, or a fragment or region thereof, bound to a support, such that said $TNF\alpha$, portion thereof or immune complex reversible binds to said immobilized chain, fragment or region to provide a bound $TNF\alpha$, portion or immune complex; and
- (b) recovering said bound $TNF\alpha$, portion or immune complex from said bound chain, fragment or region.
- 32. A method of use of a composition according to claim 1, comprising contacting said composition to human TNF α in solution, such that the contacted TNF α is neutralized with an ID50 of at least 1 μ g/ml.
- 33. A composition, comprising an anti-TNF chimeric immunoglobulin chain, comprised of at least part of a human immunoglobulin constant region and at least part of a non-human immunoglobulin variable region, said chain capable of binding an epitope specific for human TNF α .
- 34. A composition according to claim 33, wherein said chain is a neavy chain or a light chain.
- 35. A composition according to claim 33, wherein said constant region is of human origin.
- 36. A composition according to claim 33, wherein said biological activity binding of said chain to $TNF\alpha$ has a neutralizing effect on a pathologic activity of $TNF\alpha$.
- 37. A composition according to claim 33, wherein said chain has an antigen binding region which binds residues 87-108, or both 59-80 and 87-108, of hTNF α of SEQ ID NO:1.
- 38. A composition according to claim 33, wherein said chain, fragment or region does not bind to an epitope selected from the group consisting of amino acids 11-13, 37-42, 49-57 or 155-157 of hTNF α of SEQ ID NO:1.
- 39. A composition according to claim 33, wherein said chimeric immunoglobulin chain comprises two light chains and two heavy chains, each of said chains comprising at least part of a constant region and at least part of a variable

I:\gkt\app\newapp lc1v3d.app

5


10

15

20

25

30



- 40. A composition, comprising a tumor necrosis factor, TNF, inhibiting effective amount of an anti-TNF compound.
- 41. A composition according to claim 40, wherein said anti-TNF compound is an anti-TNF peptide.
- 42. A composition according to claim 41, wherein said anti-TNF peptide is selected from the group consisting of a fragment of a TNF receptor and an anti-TNF structural analog, said anti-TNF peptide capable of binding human TNF.
- 43. A composition according to claim 41, wherein said anti-TNF peptide is a fragment of a TNF receptor.
- 44. A composition according to claim 42, wherein said structural analog is capable of binding a TNF with neutralizing activity.
- 45. A composition according to claim 42, wherein said peptide further comprises a TNF binding immunoreceptor molecule, said immunoreceptor molecule, comprising at least a portion of an immunoglobulin heavy chain CH_1 region, at least a portion of a hinge region and at least one immunoglobulin light chain constant region wherein at least one immunoglobulin chain is covalently linked to a non-immunoglobulin molecule capable of binding to at least one of $TNF\alpha$ and $TNF\beta$.
- 46. A composition according to claim 45, wherein said immunoreceptor molecule further comprises at least a portion of an immunoglobulin heavy chain CH₁ region, at least a portion of a hinge region and at least one immunoglobulin light chain constant region.
- 47. A composition according to claim 47, wherein said immunoreceptor molecule further comprises at least a portion of CH_3 or CH_2 .
- 48. A composition according to claim $\underline{46}$, wherein said at least one non-immunoglobulin molecule is covalently linked to the N-terminus of at least one CH_1 region.

I:\gkt\app\newapp le1v3d.app

5

10

15

20

25

30

- 49. A composition according to claim 46, wherein said at least one non-immunoglobulin molecule is covalently linked to an interior section of at least one heavy chain region.
- 50. A composition according to claim 47, wherein said the heavy chain further comprises a variable region capable of binding to a second target molecule.
- 51. A composition according to claim 47, wherein said the heavy chain is an IgG class heavy chain.
- 52. A composition according to claim 46, wherein said the non-immunoglobulin molecule comprises at least a portion of p55.
- 53. A composition according to claim 52, wherein the non-immunoglobulin molecule comprises sequences 2-159 of p55.
- 54. A composition according to claim 49, wherein the heavy chain further comprises at least about 8 amino acids of a J region.
- 55. A composition according to claim 46, said molecule further comprising at least one additional non-immunoglobulin molecule, each non-immunoglobulin molecules comprising at least a portion of p75.
- 56. A composition according to claim 52, wherein said at least one non-immunoglobulin molecule is four non-immunoglobulin molecules, each molecule comprising at least a portion of p55.
- 57. A composition according to claim <u>55</u>, said molecule having two non-immunoglobulin molecules, each comprising at least a portion of p75.
- 58. A composition according to claim 55, said molecule having four non-immunoglobulin molecules, each comprising at least a portion of p75.
- 59. A composition according to claim 40, wherein said immunoreceptor molecule is capable of binding with high affinity to a neutralizing epitope of human $TNF\alpha$ in vivo.
- 60. A composition according to claim 33, wherein a binding affinity of said binding is at least about 1.6 \times 10¹⁰

I:\gkt\app\newapp lc1v3d.app

5

10

15

20

25

30



5

10

15

20

- 51. A composition according to claim 46, wherein said immunoreceptor molecule is capable of neutralizing TNF wherein a concentration of less than about 130 pM is capable of neutralizing about 39.2 pM human TNF α .
- 62. A composition according to claim 42, wherein said structural analog corresponds in three dimensional structure to at least a portion of a p75 or p55 extracellular region capable of binding to at least one of $TNF\alpha$ and $TNF\beta$.
- 63. A method according to claim 42, wherein said structural analog further comprises at least a portion at an immunoglobulin heavy chain CH region, at least a portion of a hinge region and at least one immunoglobulin light chain constant region.
- 64. A composition according to claim 42, wherein said anti-TNF peptide is a fragment of a TNF receptor.
- 65. A composition according to claim 64, wherein said fragment comprises at least a portion of p55.
- 66. A edmposition according to claim 65, wherein said fragment comprises sequences 2-159 of p55.
- 67. A composition according to claim 64, wherein said fragment comprises at least a portion of p75.
- 68. A composition according to claim 67, wherein said fragment comprises sequences 1-235 of p75.
- 69. A composition according to claim 68, wherein said fragment comprises sequences 1-182 of p75.
- 70. A composition according to claim 69, wherein said fragment comprises sequences 1-178 of p75.